As TGF-β displays both tumor-suppressing and tumor-promoting activities, directly inhibiting TGF-β, via TGF-β receptor kinase inhibitors or antibodies that block ligand-receptor interactions, to treat cancer remains challenging [42]. This evidence concerns the gene TGFB1 and neoplasm.